There were no significant differences in the frequency of events determining iDFS in patients stratified by molecular subtype of breast cancer with breast pCR compared to residual disease after NAC (luminal: 0.0% vs. 3.1%, p = 1.000; TNBC: 0.0% vs. 15.4%, p = 0.581; HER2+: 0.0% vs. 0.0%) (Supplementary Table S3). The gene discussed is ERBB2; the disease is breast cancer.